Молимо вас користите овај идентификатор за цитирање или овај линк до ове ставке:
https://open.uns.ac.rs/handle/123456789/7865
Назив: | Metformin in the treatment of non-alcoholic fatty liver disease: Safety, efficacy and mechanism | Аутори: | Rouabhia S. Milić, Nataša Abenavoli L. |
Датум издавања: | 1-јан-2014 | Часопис: | Expert Review of Gastroenterology and Hepatology | Сажетак: | Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease etiology worldwide. It encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis. Although the physiopathology of NAFLD is partly known. Insulin-resistance plays a central role in the development and progression of NAFLD. Several studies have indicated that metformin, as an insulin sensitizer, effectively improves NAFLD and its related metabolic status. Metformin was effective in reducing enzyme levels in the short period, but very limited and controversial information are available on liver histology. Larger randomized controlled trials of sufficient duration using clearly defined histological endpoints are needed to fully assess the efficacy of this drug in modifying the natural history of NAFLD. © Informa UK, Ltd. | URI: | https://open.uns.ac.rs/handle/123456789/7865 | ISSN: | 17474124 | DOI: | 10.1586/17474124.2014.894880 |
Налази се у колекцијама: | MDF Publikacije/Publications |
Приказати целокупан запис ставки
SCOPUSTM
Навођења
41
проверено 10.05.2024.
Преглед/и станица
4
Протекла недеља
1
1
Протекли месец
0
0
проверено 10.05.2024.
Google ScholarTM
Проверите
Алт метрика
Ставке на DSpace-у су заштићене ауторским правима, са свим правима задржаним, осим ако није другачије назначено.